The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Open accessAbstract
The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of revising the 1984 criteria for Alzheimer's disease (AD) dementia. The workgroup sought to ensure that the revised criteria would be flexible enough to be used by both general healthcare providers without access to neuropsychological testing, advanced imaging, and cerebrospinal fluid measures, and specialized investigators involved in research or in clinical trial studies who would have these tools available. We present criteria for all‐cause dementia and for AD dementia. We retained the general framework of probable AD dementia from the 1984 criteria. On the basis of the past 27 years of experience, we made several changes in the clinical criteria for the diagnosis. We also retained the term possible AD dementia, but redefined it in a manner more focused than before. Biomarker evidence was also integrated into the diagnostic formulations for probable and possible AD dementia for use in research settings. The core clinical criteria for AD dementia will continue to be the cornerstone of the diagnosis in clinical practice, but biomarker evidence is expected to enhance the pathophysiological specificity of the diagnosis of AD dementia. Much work lies ahead for validating the biomarker diagnosis of AD dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A consensus meeting was held among the study neurologists and neuropsychologists to clinically determine each potential participant’s cognitive status grouping (NC, MCI, or dementia) based on a standardized approach used in National Institute of Health (NIH)-funded Alzheimer’s Disease Centers across the United States (Albert et al., 2011; Jack et al., 2011; McKhann et al., 2011).”
From Internet-Based Conversational Engagement Randomized Controlled Clinical Trial (I-CONECT) Among Socially Isolated Adults 75+ Years Old With Normal Cognition or Mild Cognitive Impairment: Topline Results (2024) · cites this paper as McKhann et al., 2011
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the atrophy of specific brain regions shown by structural MRI is an important part of the diagnostic criteria for FTD and AD (McKhann et al., 2011; Rascovsky et al., 2011)”
From Deep Learning-Based Classification and Voxel-Based Visualization of Frontotemporal Dementia and Alzheimer's Disease (2021) · cites this paper as McKhann et al., 2011
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Diagnosis of AD was made in accordance with the NINCDS-ADRCA criteria (McKhann et al., 2011) and MCI was diagnosed according to the Mayo criteria (Petersen et al., 1999).”
From Mean diffusivity in cortical gray matter in Alzheimer's disease: The importance of partial volume correction (2018) · cites this paper as McKhann et al., 2011
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“During this extended preclinical period prior to the dementia diagnosis, many patients develop behavioral or neuropsychiatric changes, including agitation, irritability, decreased motivation, loss of empathy, and depression, which increase the risk of transition to mild cognitive impairment and AD.12-14”
From Machine learning reveals prominent spontaneous behavioral changes and treatment efficacy in humanized and transgenic Alzheimer's disease models (2024) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“All patients (n = 96) were clinically evaluated by expert neurologists (M.G., D.J.I.) at the time of recording at the frontotemporal degeneration center (FTDC) in the neurology department of the Hospital of the University of Pennsylvania, and they were classified at a weekly consensus meeting at the FTDC using established clinical criteria.”
From Automatic classification of AD pathology in FTD phenotypes using natural speech (2024) · cites this paper as [26]
The cited source says what the claim attributes to it.
In the citing paper
“AD is clinically diagnosed using the 2011 National Institute on Aging-Alzheimer's Association (NIA-AA) criteria [5].”
From Identification of novel diagnostic panel for mild cognitive impairment and Alzheimer’s disease: findings based on urine proteomics and machine learning (2023) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“Probable AD diagnoses were assigned according to both NINCDS/ADRDA criteria (23), and the core clinical NIA-AA criteria (28).”
From SUCLG2 identified as both a determinator of CSF Aβ1–42 levels and an attenuator of cognitive decline in Alzheimer's disease (2014) · cites this paper as [28]
In the citing paper
“The University of California San Francisco (UCSF) Memory and Aging Center Dementia cohort consisted of 152 carefully phenotyped older adults meeting the National Institute on Aging-Alzheimer's Association (NIA-AA) criteria for either mild-cognitive impairment22 or probable dementia because of AD.23”
From Whole-genome sequencing suggests a chemokine gene cluster that modifies age at onset in familial Alzheimer's disease (2015) · cites this paper as [23]
In the citing paper
“More recently, the imaging of amyloid with compounds such as the radiolabeled Pittsburgh compound B (11C-PiB) has received much interest and been proposed as a biomarker of AD.21,22”
From Diagnostic Criteria for Vascular Cognitive Disorders: A VASCOG Statement (2014) · cites this paper as [21]
In the citing paper
“These, along with amyloid imaging using positron emission tomography (PET), may help determine AD as the main or contributory cause of the cognitive disorder.”
From Diagnostic Criteria for Vascular Cognitive Disorders: A VASCOG Statement (2014) · cites this paper as [21]
In the citing paper
“CSF markers for AD are, however, better developed, with lower levels of Aβ42 and elevated levels of tau/phosphorylated-tau being indicative of AD pathology.21,22”
From Diagnostic Criteria for Vascular Cognitive Disorders: A VASCOG Statement (2014) · cites this paper as [21]
In the citing paper
“The clinical criteria used most commonly are the NIA‐AA criteria for dementia 89 and mild cognitive impairment 90 due to Alzheimer's disease.”
From Mental health care for older adults: recent advances and new directions in clinical practice and research (2022) · cites this paper as [89]
In the citing paper
“The development of the DSM-5 criteria for the various subtypes involved extensive discussions with experts from diverse fields to harmonize the DSM criteria with criteria developed by other expert groups, such as the NIA-AA, 20,27 the frontotemporal dementia expert group, 28,29 the consortium on DLB, 30 the VASCOG working group, 31 the Movement Disorder Study Task Force on Parkinson Disease 32 and”
From Classifying neurocognitive disorders: the DSM-5 approach (2014) · cites this paper as [27]
In the citing paper
“This different pattern of results in bvFTD and AD may reflect the preferential and widespread damage within the AIN in bvFTD11,14,16, 17, 18, 19, 20,24 whereas in AD, AIN damage appears to be more circumscribed.17,38,88”
From Altered spatiotemporal brain dynamics of interoception in behavioural-variant frontotemporal dementia (2025) · cites this paper as [38]
In the citing paper
“Second, patients received diagnoses based on established clinical criteria only,37,38 without testing for ATN biomarkers in AD such as the deposition of amyloid-β and tau proteins established via Positron Emission Tomography, CSF, or plasma in AD.94, 95, 96, 97”
From Altered spatiotemporal brain dynamics of interoception in behavioural-variant frontotemporal dementia (2025) · cites this paper as [38]
In the citing paper
“The diagnosis was concluded in a multidisciplinary meeting using consensus criteria for probable FTD, PPD (DSM-V), and AD [25,31,32].”
In the citing paper
“Detection of abnormal Aβ accumulation (Aβ positivity) may support the clinical diagnosis of AD1,2 and is essential for including participants in clinical AD trials targeting Aβ.3”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [2]
In the citing paper
“Diagnosis was established by the multidisciplinary teams at each research institute based on current consensus diagnostic criteria (McKhann et al., 2011; Postuma et al., 2015; Rascovsky et al., 2011).”
From Thinking versus feeling: How interoception and cognition influence emotion recognition in behavioural-variant frontotemporal dementia, Alzheimer's disease, and Parkinson's disease (2023) · cites this paper as McKhann et al., 2011
In the citing paper
“AD patients present with predominant episodic memory loss and impaired executive functioning, with atrophy observed in the medial temporal lobe, most notably in the hippocampus and posterior cingulate (McKhann et al., 2011).”
From Thinking versus feeling: How interoception and cognition influence emotion recognition in behavioural-variant frontotemporal dementia, Alzheimer's disease, and Parkinson's disease (2023) · cites this paper as McKhann et al., 2011
In the citing paper
“A diagnosis of probable AD had been made prior to the study by neurologists at the Memory Center according to the clinical criteria of the National Institute on Aging and the Alzheimer’s Association criteria for probable AD [1].”
From The effects of confinement on neuropsychiatric symptoms in Alzheimer's disease during the COVID-19 crisis (2020) · cites this paper as [1]
In the citing paper
“The 3 major clinical criteria for the AD spectrum are the revised 2011 NIA-AA criteria, 32,39 the International Working Group (Dubois and colleagues 39,40 ) 2010 revised new lexicon criteria, and the Diagnostic and Statistical Manual of Mental Disorders, 5th edition criteria.41”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [32]
In the citing paper
“The 2011 National Institute on Aging and Alzheimer's Association (NIA-AA) criteria for AD recognizes nonamnestic AD presentations that include language, visuospatial, and executive dysfunction features.32”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [32]
In the citing paper
“dementia-level impairment requires cognitive or behavioral symptoms”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [32]
In the citing paper
“MCI diagnosis is a matter of”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [32]
In the citing paper
“With the advent of biomarkers that enable in vivo identification of underlying AD pathological conditions, and the acceptance that AD begins years before the emergence of cognitive impairment, AD is now commonly accepted as a clinicopathological entity7,8 that can be diagnosed without histopathological examination, in the presence of appropriate biomarker evidence of an underlying condition.6,8,9”
From Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Self-citationAlbert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 7×
“Initial efforts to incorporate biomarkers into the diagnosis of AD dementia and MCI [14] need to be coupled with a more comprehensive approach to the diagnostic process.”
BackgroundInfluentialSelf-citationMild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citationClassification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141
Self-citationDiagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946
Self-citationRomán, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
Flagged first, then by citations
Cited by
Sorted by citations
Items 1,201–1,300 of 1,532
Tarnanas, I., Tsolaki, M., Nef, T., M. Müri, R., & Mosimann, U. P. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.01.002 · Cited by 77
Robitaille, A., van den Hout, A., Machado, R. J. M., Bennett, D. A., Čukić, I., Deary, I. J., Hofer, S. M., Hoogendijk, E. O., Huisman, M., Johansson, B., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.10.003 · Cited by 77
Peet, B. T., Spina, S., Mundada, N., & La Joie, R. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01101-x · Cited by 74
DNA Hypomethylation in Blood Links B3GALT4 and ZADH2 to Alzheimer’s Disease
Madrid, A., Hogan, K. J., Papale, L. A., Clark, L. R., Asthana, S., Johnson, S. C., & Alisch, R. S. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180592 · Cited by 77
Effect of cholinergic treatment depends on cholinergic integrity in early Alzheimer’s disease
Richter, N., Beckers, N., Onur, O. A., Dietlein, M., Tittgemeyer, M., Kracht, L., Neumaier, B., Fink, G. R., & Kukolja, J. (2018) · Brain · doi:10.1093/brain/awx356 · Cited by 77
Chapleau, M., Aldebert, J., Montembeault, M., & Brambati, S. M. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160382 · Cited by 73
MARIO Project: validation and evidence of service robots for older people with dementia
D’Onofrio, G., Sancarlo, D., Raciti, M., Burke, M., Teare, A., Kovacic, T., Cortis, K., Murphy, K., Barrett, E., Whelan, S., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181165 · Cited by 76
Gaugler, J. E., Ascher-Svanum, H., Roth, D. L., Fafowora, T., Siderowf, A., & Beach, T. G. (2013) · BMC Geriatrics · doi:10.1186/1471-2318-13-137 · Cited by 97
“The clinical diagnosis of AD is a challenging evaluation process that follows established clinical criteria and requires elimination of other potential causes for dementia [2,3].”
BackgroundRogers, K., Felsenstein, K. M., Hrdlicka, L., Tu, Z., Albayya, F., Lee, W., Hopp, S., Miller, M.-J., Spaulding, D., Yang, Z., et al. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-61 · Cited by 75
Chandler, M. J., Locke, D. E., Crook, J. E., Fields, J. A., Ball, C. T., Phatak, V. S., Dean, P. M., Morris, M., & Smith, G. E. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.3016 · Cited by 75
Warshaw, G. A., & Bragg, E. J. (2014) · Health Affairs · doi:10.1377/hlthaff.2013.1232 · Cited by 75
IL-33 and its decoy sST2 in patients with Alzheimer’s disease and mild cognitive impairment
Saresella, M., Marventano, I., Piancone, F., La Rosa, F., Galimberti, D., Fenoglio, C., Scarpini, E., & Clerici, M. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01806-4 · Cited by 75
Hu, J., Qing, Z., Liu, R., Zhang, X., Lv, P., Wang, M., Wang, Y., He, K., Gao, Y., & Zhang, B. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.626154 · Cited by 70
“Among them, the atrophy of specific brain regions shown by structural MRI is an important part of the diagnostic criteria for FTD and AD (McKhann et al., 2011; Rascovsky et al., 2011), and magnetic resonance scanning has become a standard procedure in the clinical workflow.”
BackgroundDeleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer’s disease
On behalf of the European Early-Onset Dementia (EU EOD) consortium, De Roeck, A., Van den Bossche, T., van der Zee, J., Verheijen, J., De Coster, W., Van Dongen, J., Dillen, L., Baradaran-Heravi, Y., Heeman, B., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1714-x · Cited by 74
Apathy is associated with increased amyloid burden in mild cognitive impairment
Marshall, G. A., Donovan, N. J., Lorius, N., Gidicsin, C. M., Maye, J., Pepin, L. C., Becker, J. A., Amariglio, R. E., Rentz, D. M., Sperling, R. A., et al. (2013) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/appi.neuropsych.12060156 · Cited by 73
Neocortical origin and progression of gray matter atrophy in nonamnestic Alzheimer's disease
Phillips, J. S., Da Re, F., Dratch, L., Xie, S. X., Irwin, D. J., McMillan, C. T., Vaishnavi, S. N., Ferrarese, C., Lee, E. B., Shaw, L. M., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.11.008 · Cited by 74
Zucchella, C., Federico, A., Martini, A., Tinazzi, M., Bartolo, M., & Tamburin, S. (2018) · Practical Neurology · doi:10.1136/practneurol-2017-001743 · Cited by 74
Munawara, U., Catanzaro, M., Xu, W., Tan, C., Hirokawa, K., Bosco, N., Dumoulin, D., Khalil, A., Larbi, A., Lévesque, S., et al. (2021) · Immunity & Ageing · doi:10.1186/s12979-021-00236-x · Cited by 74
Relationship between frailty and Alzheimer's disease biomarkers: a scoping review
Wallace, L., Theou, O., Rockwood, K., & Andrew, M. K. (2018) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.05.002 · Cited by 72
Low-dose ladostigil for mild cognitive impairment: A phase 2 placebo-controlled clinical trial
Schneider, L. S., Geffen, Y., Rabinowitz, J., Thomas, R. G., Schmidt, R., Ropele, S., Weinstock, M., & on behalf of the Ladostigil Study Group (2019) · Neurology · doi:10.1212/wnl.0000000000008239 · Cited by 75
Allostatic interoceptive overload in frontotemporal dementia
Birba, A., Santamaría-García, H., Prado, P., Cruzat, J., Ballesteros, A. S., Legaz, A., Fittipaldi, S., Duran-Aniotz, C., Slachevsky, A., Santibañez, R., et al. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.02.955 · Cited by 70
Using genetics to enable studies on the prevention of Alzheimer's disease
Crenshaw, D. G., Gottschalk, W. K., Lutz, M. W., Grossman, I., Saunders, A. M., Burke, J. R., Welsh-Bohmer, K. A., Brannan, S. K., Burns, D. K., & Roses, A. D. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.222 · Cited by 70
Tsolaki, A. C., Kosmidou, V., Kompatsiaris, I. (., Papadaniil, C., Hadjileontiadis, L., Adam, A., & Tsolaki, M. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.03.025 · Cited by 70
Granot‐Hershkovitz, E., Tarraf, W., Kurniansyah, N., Daviglus, M., Isasi, C. R., Kaplan, R., Lamar, M., Perreira, K. M., Wassertheil‐Smoller, S., Stickel, A., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12205 · Cited by 71
Sarto, J., Ruiz-García, R., Guillén, N., Ramos-Campoy, Ó., Falgàs, N., Esteller, D., Contador, J., Fernández, G., González, Y., Tort-Merino, A., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000201597 · Cited by 71
Mak, E., Gabel, S., Mirette, H., Su, L., Williams, G. B., Waldman, A., Wells, K., Ritchie, K., Ritchie, C., & O’Brien, J. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2016.10.001 · Cited by 71
Cerebral white matter lesions – associations with Aβ isoforms and amyloid PET
van Westen, D., Lindqvist, D., Blennow, K., Minthon, L., Nägga, K., Stomrud, E., Zetterberg, H., & Hansson, O. (2016) · Scientific Reports · doi:10.1038/srep20709 · Cited by 66
Na, R., Yang, J.-H., Yeom, Y., Kim, Y. J., Byun, S., Kim, K., & Kim, K. W. (2019) · Psychiatry Investigation · doi:10.30773/pi.2019.02.11.2 · Cited by 70
Schmitter-Edgecombe, M., & Dyck, D. G. (2014) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617714000782 · Cited by 70
Dysregulated Wnt Signalling in the Alzheimer’s Brain
Aghaizu, N. D., Jin, H., & Whiting, P. J. (2020) · Brain Sciences · doi:10.3390/brainsci10120902 · Cited by 70
Dong, J. W., Jelescu, I. O., Ades-Aron, B., Novikov, D. S., Friedman, K., Babb, J. S., Osorio, R. S., Galvin, J. E., Shepherd, T. M., & Fieremans, E. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.01.009 · Cited by 70
Yang, H., Oh, C.-K., Amal, H., Wishnok, J. S., Lewis, S., Schahrer, E., Trudler, D., Nakamura, T., Tannenbaum, S. R., & Lipton, S. A. (2022) · Science Advances · doi:10.1126/sciadv.ade0764 · Cited by 70
Mao, C., Xu, J., Rasmussen, L., Li, Y., Adekkanattu, P., Pacheco, J., Bonakdarpour, B., Vassar, R., Shen, L., Jiang, G., et al. (2023) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2023.104442 · Cited by 67
Selected Findings from the Religious Orders Study and Rush Memory and Aging Project
Bennett, D. A., Wilson, R. S., Arvanitakis, Z., Boyle, P. A., de Toledo-Morrell, L., & Schneider, J. A. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129007 · Cited by 69
ABCA7 rare variants and Alzheimer disease risk
Le Guennec, K., Nicolas, G., Quenez, O., Charbonnier, C., Wallon, D., Bellenguez, C., Grenier-Boley, B., Rousseau, S., Richard, A.-C., Rovelet-Lecrux, A., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002627 · Cited by 69
Fantoni, E. R., Chalkidou, A., O’ Brien, J. T., Farrar, G., & Hammers, A. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171093 · Cited by 68
Knopman, D. S., Jack, C. R., Wiste, H. J., Weigand, S. D., Vemuri, P., Lowe, V. J., Kantarci, K., Gunter, J. L., Senjem, M. L., Mielke, M. M., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.182 · Cited by 68
Self-citationChallenges associated with biomarker‐based classification systems for Alzheimer's disease
Illán‐Gala, I., Pegueroles, J., Montal, V., Vilaplana, E., Carmona‐Iragui, M., Alcolea, D., Dickerson, B. C., Sánchez‐Valle, R., de Leon, M. J., Blesa, R., et al. (2018) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.03.004 · Cited by 62
Pathophysiology of Alzheimer’s Disease
Yarns, B. C., Holiday, K. A., Carlson, D. M., Cosgrove, C. K., & Melrose, R. J. (2022) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2022.07.003 · Cited by 68
Szewieczek, J., Mazur, K., & Wilczyński, K. (2016) · Clinical Interventions in Aging · doi:10.2147/cia.s115755 · Cited by 67
Irish, M., Landin-Romero, R., Mothakunnel, A., Ramanan, S., Hsieh, S., Hodges, J. R., & Piguet, O. (2018) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2017.03.014 · Cited by 65
Udeh-Momoh, C., & Watermeyer, T. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101459 · Cited by 67
The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer’s disease
for the Dominantly Inherited Alzheimer Network (DIAN), Twohig, D., Rodriguez-Vieitez, E., Sando, S. B., Berge, G., Lauridsen, C., Møller, I., Grøntvedt, G. R., Bråthen, G., Patra, K., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0624-z · Cited by 68
Self-citationBorba, E. M., Duarte, J. A., Bristot, G., Scotton, E., Camozzato, A. L., & Chaves, M. L. F. (2016) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000450601 · Cited by 67
Combining drug and music therapy in patients with moderate Alzheimer's disease: a randomized study
Giovagnoli, A. R., Manfredi, V., Schifano, L., Paterlini, C., Parente, A., & Tagliavini, F. (2018) · Neurological Sciences · doi:10.1007/s10072-018-3316-3 · Cited by 67
Horr, T., Messinger-Rapport, B., & Pillai, J. A. (2015) · The Journal of nutrition, health and aging · doi:10.1007/s12603-014-0565-6 · Cited by 67
Selective Secretase Targeting for Alzheimer’s Disease Therapy
Miranda, A., Montiel, E., Ulrich, H., & Paz, C. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201027 · Cited by 66
“…injury is not uniform, being most severe in the neocortex and hippocampus, affecting different functional regions of the brain [5], such as learning and memory process and subsequent deficits in attention, motor function, language, gnosis, and visuospatial function as well as social behavior [6].”
Zhang, S., Smailagic, N., Hyde, C., Noel-Storr, A. H., Takwoingi, Y., McShane, R., & Feng, J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010386.pub2 · Cited by 66
Mak, E., Gabel, S., Su, L., Williams, G. B., Arnold, R., Passamonti, L., Vazquez Rodríguez, P., Surendranathan, A., Bevan-Jones, W. R., Rowe, J. B., et al. (2017) · International Psychogeriatrics · doi:10.1017/s1041610216002143 · Cited by 66
Seo, S. W., Ayakta, N., Grinberg, L. T., Villeneuve, S., Lehmann, M., Reed, B., DeCarli, C., Miller, B. L., Rosen, H. J., Boxer, A. L., et al. (2017) · NeuroImage: Clinical · doi:10.1016/j.nicl.2016.11.008 · Cited by 63
Measuring cognitive change in subjects with prodromal Alzheimer’s disease
Mura, T., Proust-Lima, C., Jacqmin-Gadda, H., Akbaraly, T. N., Touchon, J., Dubois, B., & Berr, C. (2014) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-305078 · Cited by 64
Solfrizzi, V., and for the Italian Longitudinal Study on Aging Working Group 2, Panza, F., Imbimbo, B. P., D’Introno, A., Galluzzo, L., Gandin, C., Misciagna, G., Guerra, V., Osella, A., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150333 · Cited by 65
Neurofilament relates to white matter microstructure in older adults
Moore, E. E., Hohman, T. J., Badami, F. S., Pechman, K. R., Osborn, K. E., Acosta, L. M. Y., Bell, S. P., Babicz, M. A., Gifford, K. A., Anderson, A. W., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.06.023 · Cited by 65
Rovner, B. W., Casten, R. J., Hegel, M. T., & Leiby, B. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.2513 · Cited by 64
Clinical and research diagnostic criteria for Alzheimer's disease
Sarazin, M., de Souza, L. C., Lehéricy, S., & Dubois, B. (2012) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2011.11.004 · Cited by 64
Lee, E., Choi, J.-S., Kim, M., & Suk, H.-I. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.116113 · Cited by 61
Roses, A. D., Lutz, M. W., Crenshaw, D. G., Grossman, I., Saunders, A. M., & Gottschalk, W. K. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.10.009 · Cited by 63
Henf, J., Grothe, M. J., Brueggen, K., Teipel, S., & Dyrba, M. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2017.10.005 · Cited by 64
Daianu, M., Mendez, M. F., Baboyan, V. G., Jin, Y., Melrose, R. J., Jimenez, E. E., & Thompson, P. M. (2016) · Brain Imaging and Behavior · doi:10.1007/s11682-015-9458-5 · Cited by 64
Snyder, C. M., Fauth, E., Wanzek, J., Piercy, K. W., Norton, M. C., Corcoran, C., Rabins, P. V., Lyketsos, C. G., & Tschanz, J. T. (2015) · Aging & Mental Health · doi:10.1080/13607863.2014.939610 · Cited by 63
APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease
Quiroz, Y. T., Aguillon, D., Aguirre-Acevedo, D. C., Vasquez, D., Zuluaga, Y., Baena, A. Y., Madrigal, L., Hincapié, L., Sanchez, J. S., Langella, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2308583 · Cited by 63
The prevalence of obstructive sleep apnea in mild cognitive impairment: a systematic review
Mubashir, T., Abrahamyan, L., Niazi, A., Piyasena, D., Arif, A. A., Wong, J., Osorio, R. S., Ryan, C. M., & Chung, F. (2019) · BMC Neurology · doi:10.1186/s12883-019-1422-3 · Cited by 65
Makedonov, I., Black, S. E., & MacIntosh, B. J. (2013) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03785.x · Cited by 62
Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease
Alexopoulos, P., Kriett, L., Haller, B., Klupp, E., Gray, K., Grimmer, T., Laskaris, N., Förster, S., Perneczky, R., Kurz, A., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.03.006 · Cited by 62
A Conversational Robot for Older Adults with Alzheimer's Disease
Pou-Prom, C., Raimondo, S., & Rudzicz, F. (2020) · ACM Transactions on Human-Robot Interaction · doi:10.1145/3380785 · Cited by 59
Assessing the “social brain” in dementia: applying TASIT-S
Kumfor, F., Honan, C., McDonald, S., Hazelton, J. L., Hodges, J. R., & Piguet, O. (2017) · Cortex · doi:10.1016/j.cortex.2017.05.022 · Cited by 58
“Diagnosis for bvFTD and AD was determined by consensus between the behavioural neurologist, neuropsychologist and occupational therapist according to current consensus criteria (McKhann et al. 2011; Rascovsky et al. 2011).”
Skillbäck, T., Mattsson, N., Hansson, K., Mirgorodskaya, E., Dahlén, R., van der Flier, W., Scheltens, P., Duits, F., Hansson, O., Teunissen, C., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13831-0 · Cited by 61
Self-citationSmailagic, N., Lafortune, L., Kelly, S., Hyde, C., & Brayne, C. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171125 · Cited by 61
A Cochrane review on brain [18F]FDG PET in dementia: limitations and future perspectives
On behalf of the European Association of Nuclear Medicine, Morbelli, S., Garibotto, V., Van De Giessen, E., Arbizu, J., Chételat, G., Drezgza, A., Hesse, S., Lammertsma, A. A., Law, I., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3098-2 · Cited by 61
In vivo direct relation of tau pathology with neuroinflammation in early Alzheimer’s disease
Terada, T., Yokokura, M., Obi, T., Bunai, T., Yoshikawa, E., Ando, I., Shimada, H., Suhara, T., Higuchi, M., & Ouchi, Y. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09400-2 · Cited by 60
Akhtar, R. S., Licata, J. P., Luk, K. C., Shaw, L. M., Trojanowski, J. Q., & Lee, V. M. ‐. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14330 · Cited by 60
Vidoni, E. D., Perales, J., Alshehri, M., Giles, A.-M., Siengsukon, C. F., & Burns, J. M. (2019) · Journal of Geriatric Physical Therapy · doi:10.1519/jpt.0000000000000172 · Cited by 61
Agitation-associated behavioral symptoms in mild cognitive impairment and Alzheimer's dementia
Van der Mussele, S., Le Bastard, N., Saerens, J., Somers, N., Mariën, P., Goeman, J., De Deyn, P. P., & Engelborghs, S. (2015) · Aging & Mental Health · doi:10.1080/13607863.2014.924900 · Cited by 60
Energy expenditure in frontotemporal dementia: a behavioural and imaging study
Ahmed, R. M., Landin-Romero, R., Collet, T.-H., van der Klaauw, A. A., Devenney, E., Henning, E., Kiernan, M. C., Piguet, O., Farooqi, I. S., & Hodges, J. R. (2017) · Brain · doi:10.1093/brain/aww263 · Cited by 58
Jalilianhasanpour, R., Beheshtian, E., Sherbaf, G., Sahraian, S., & Sair, H. I. (2019) · Topics in Magnetic Resonance Imaging · doi:10.1097/rmr.0000000000000223 · Cited by 57
Pan, X., Chen, Z., Fei, G., Pan, S., Bao, W., Ren, S., Guan, Y., & Zhong, C. (2016) · Neuroscience Bulletin · doi:10.1007/s12264-016-0067-0 · Cited by 59
Krudop, W. A., Dols, A., Kerssens, C. J., Eikelenboom, P., Prins, N. D., Möller, C., Schouws, S., Rhebergen, D., van Exel, E., van der Flier, W. M., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170608 · Cited by 57
Self-citationTouchscreen games to detect cognitive impairment in senior adults. A user-interaction pilot study
Valladares-Rodriguez, S., Fernández-Iglesias, M. J., Anido-Rifón, L., Facal, D., Rivas-Costa, C., & Pérez-Rodríguez, R. (2019) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2019.04.012 · Cited by 55
Grill, J. D., Di, L., Lu, P. H., Lee, C., Ringman, J., Apostolova, L. G., Chow, N., Kohannim, O., Cummings, J. L., Thompson, P. M., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.03.006 · Cited by 58
Bachli, M. B., Sedeño, L., Ochab, J. K., Piguet, O., Kumfor, F., Reyes, P., Torralva, T., Roca, M., Cardona, J. F., Campo, C. G., et al. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2019.116456 · Cited by 57
Temporal irreversibility of large-scale brain dynamics in Alzheimer's disease
Cruzat, J., Herzog, R., Prado, P., Sanz-Perl, Y., Gonzalez-Gomez, R., Moguilner, S., Kringelbach, M. L., Deco, G., Tagliazucchi, E., & Ibañez, A. (2023) · The Journal of Neuroscience · doi:10.1523/jneurosci.1312-22.2022 · Cited by 57
Fink, H. A., Linskens, E. J., Silverman, P. C., McCarten, J. R., Hemmy, L. S., Ouellette, J. M., Greer, N. L., Wilt, T. J., & Butler, M. (2020) · Annals of Internal Medicine · doi:10.7326/m19-3888 · Cited by 57
Wei, G., Irish, M., Hodges, J. R., Piguet, O., & Kumfor, F. (2020) · Journal of Neurology · doi:10.1007/s00415-019-09679-1 · Cited by 54
Lin, Y.-C., Shih, Y.-C., Tseng, W.-Y. I., Chu, Y.-H., Wu, M.-T., Chen, T.-F., Tang, P.-F., & Chiu, M.-J. (2014) · Brain Topography · doi:10.1007/s10548-013-0346-2 · Cited by 56
Wang, X., Liu, G., Gao, Q., Li, N., & Wang, R. (2020) · Acta Neurologica Scandinavica · doi:10.1111/ane.13196 · Cited by 51
Sedeño, L., Piguet, O., Abrevaya, S., Desmaras, H., García‐Cordero, I., Baez, S., Alethia de la Fuente, L., Reyes, P., Tu, S., Moguilner, S., et al. (2017) · Human Brain Mapping · doi:10.1002/hbm.23627 · Cited by 55
Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome
Tetzloff, K. A., Duffy, J. R., Clark, H. M., Utianski, R. L., Strand, E. A., Machulda, M. M., Botha, H., Martin, P. R., Schwarz, C. G., Senjem, M. L., et al. (2019) · Brain · doi:10.1093/brain/awz157 · Cited by 55
Self-citationPrevalence of obstructive sleep apnea in Alzheimer’s disease patients
Gaeta, A. M., Benítez, I. D., Jorge, C., Torres, G., Dakterzada, F., Minguez, O., Huerto, R., Pujol, M., Carnes, A., Dalmases, M., et al. (2020) · Journal of Neurology · doi:10.1007/s00415-019-09668-4 · Cited by 55
Educational disparities in brain health and dementia across Latin America and the United States
Gonzalez‐Gomez, R., Legaz, A., Moguilner, S., Cruzat, J., Hernández, H., Baez, S., Cocchi, R., Coronel‐Olivero, C., Medel, V., Tagliazuchi, E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.14085 · Cited by 55
Distinct populations of highly potent TAU seed conformers in rapidly progressing Alzheimer’s disease
Kim, C., Haldiman, T., Kang, S.-G., Hromadkova, L., Han, Z. Z., Chen, W., Lissemore, F., Lerner, A., de Silva, R., Cohen, M. L., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abg0253 · Cited by 55
Garcia, G., Pinto, S., Ferreira, S., Lopes, D., Serrador, M. J., Fernandes, A., Vaz, A. R., Mendonça, A. D., Edenhofer, F., Malm, T., et al. (2022) · Cells · doi:10.3390/cells11213377 · Cited by 55
Dodge, H. H., Yu, K., Wu, C.-Y., Pruitt, P. J., Asgari, M., Kaye, J. A., Hampstead, B. M., Struble, L., Potempa, K., Lichtenberg, P., et al. (2024) · The Gerontologist · doi:10.1093/geront/gnad147 · Cited by 56
Chen, X., Zhang, W., Lin, Z., Zheng, C., Chen, S., Zhou, H., & Liu, Z. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1103189 · Cited by 55
Koh, S.-H., Choi, S. H., Jeong, J. H., Jang, J.-W., Park, K. W., Kim, E.-J., Kim, H. J., Hong, J. Y., Yoon, S. J., Yoon, B., et al. (2020) · Aging · doi:10.18632/aging.102893 · Cited by 51
Tong, T., Ledig, C., Guerrero, R., Schuh, A., Koikkalainen, J., Tolonen, A., Rhodius, H., Barkhof, F., Tijms, B., Lemstra, A. W., et al. (2017) · NeuroImage: Clinical · doi:10.1016/j.nicl.2017.06.012 · Cited by 54
Toward the Automation of Diagnostic Conversation Analysis in Patients with Memory Complaints
Mirheidari, B., Blackburn, D., Harkness, K., Walker, T., Venneri, A., Reuber, M., & Christensen, H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160507 · Cited by 54
Subtyping of mild cognitive impairment using a deep learning model based on brain atrophy patterns
Kwak, K., Giovanello, K. S., Bozoki, A., Styner, M., & Dayan, E. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100467 · Cited by 47
Mayeda, E. R. (2019) · American Journal of Epidemiology · doi:10.1093/aje/kwz047 · Cited by 52
Two‐level diagnostic classification using cerebrospinal fluid YKL‐40 in Alzheimer's disease
Baldacci, F., Toschi, N., Lista, S., Zetterberg, H., Blennow, K., Kilimann, I., Teipel, S., Cavedo, E., dos Santos, A. M., Epelbaum, S., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.01.021 · Cited by 53
Devanand, D. P., Pelton, G. H., D'Antonio, K., Ciarleglio, A., Scodes, J., Andrews, H., Lunsford, J., Beyer, J. L., Petrella, J. R., Sneed, J., et al. (2018) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2018.05.008 · Cited by 47
Metadata
- Authors
- McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., Mohs, R. C., Morris, J. C., Rossor, M. N., Scheltens, P., Carrillo, M. C., Thies, B., Weintraub, S., & Phelps, C. H.
- Affiliations
- Johns Hopkins University (US)
- Mayo Clinic (US)
- Lady Davis Institute for Medical Research (CA)
- Harvard University (US)
- University of California, Irvine (US)
- University of Pittsburgh (US)
- National Institute of Neurological Disorders and Stroke (US)
- Columbia University Irving Medical Center (US)
- Eli Lilly (United States) (US)
- Washington University in St. Louis (US)
- UCL Queen Square Institute of Neurology (GB)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Alzheimer's Association Chicago IL USA
- Alzheimer's Association (US)
- Department of Psychiatry Northwestern Feinberg School of Medicine Chicago IL USA
- National Institutes of Health (US)
- Corresponding author
- McKhann, Guy M.
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2011-04-22
- Volume
- 7
- Issue
- 3
- Pages
- 263-269
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- PMC
- PMC3312024
- OpenAlex
- W2115017507
- Semantic Scholar
- 37d2d04f8c09da1f0cf8434a38a51841b5b703bf
- Cited by
- 18,657
- References
- 44
- Citations by year
- 2026: 893 · 2025: 1313 · 2024: 1585 · 2023: 1543 · 2022: 1670 · 2021: 1796 · 2020: 1602 · 2019: 1448 · 2018: 1297 · 2017: 1200 · 2016: 1088 · 2015: 1062 · 2014: 794 · 2013: 715 · 2012: 491
- FWCI
- 471.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Alzheimer s & Dementia (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- National Institute on Aging
- Forest Pharmaceuticals
- Alzheimer's Association
- Fidelity Biosciences
- Baxter International
- Pfizer
- Johnson and Johnson
- Avid Radiopharmaceuticals
- GE Healthcare
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, dementia diagnosis
- MeSH terms
- Alzheimer Disease, Diagnosis, Differential, Diagnostic Imaging, Humans, Societies, Medical, United States, Biomarkers, Practice Guidelines as Topic, Disease Progression, National Institute on Aging (U.S.)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
